Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RYR2 | Q92736 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29517134 | 1.00 | RYR2 (0.36) | RYR2TSHRCES1HTR2CHPGD | |
| SCHEMBL1718843 | 0.92 | RYR2 (0.32) | RYR2TSHRCES1ALDH1A1GAA | |
| SCHEMBL9117617 | 0.86 | TSHR (0.44) | RYR2TSHRCES1HTR2CHPGD | |
| SCHEMBL1869023 | 0.79 | NAMPT (0.33) | RYR2ALDH1A1 | |
| SCHEMBL450053 | 0.75 | — | — | |
| SCHEMBL1012871 | 0.75 | — | — | |
| SCHEMBL29387129 | 0.75 | — | — | |
| SCHEMBL8997 | 0.75 | — | — | |
| SCHEMBL10580638 | 0.73 | ALDH1A1 (0.34) | RYR2TSHRHPGDALDH1A1KDM4E | |
| SCHEMBL28923936 | 0.73 | ALDH1A1 (0.34) | RYR2TSHRHPGDALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1649 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109952652-B | Imaging element, stacked imaging element, imaging device, and electronic device | 索尼公司 | 2023-09-19 | — | — | CN | claimed |
| EP-3658141-B1 | TREATING PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPALPHA - CD47 INTERACTION | STICHTING HET NEDERLANDS KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL) | 2022-11-16 | — | — | EP | claimed |
| EP-1852420-B1 | Indole compounds for treating respiratory disorders | ONO PHARMACEUTICAL CO (JP) | 2012-10-17 | — | — | EP | claimed |
| EP-1713780-B1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2012-01-18 | — | — | EP | claimed |
| JP-4806628-B2 | — | — | 2011-11-02 | — | — | JP | claimed |
| US-20100159032-A1 | COMBINATIONS USEFUL FOR THE TREATMENT OF NEURONAL DISORDERS | PROBIODRUG AG (DE) | 2010-06-24 | — | — | US | claimed |
| EP-1620091-B1 | INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2010-03-31 | — | — | EP | claimed |
| US-7402580-B2 | Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-07-22 | — | — | US | claimed |
| US-7371871-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2008-05-13 | — | — | US | claimed |
| EP-1620091-A2 | INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2006-02-01 | — | — | EP | claimed |
| WO-2004098591-A2 | INHIBITORS OF GLUTAMINYL CYCLASE AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES | PROBIODRUG AG (DE) | 2004-11-18 | — | — | WO | claimed |
| US-20040224875-A1 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2004-11-11 | — | — | US | claimed |
| US-5403936-A | Irradiating organic optical material comprising oxazoline derivative with light | KABUSHIKI KAISHA TOSHIBA (JP) | 1995-04-04 | — | — | US | claimed |
| US-12630510-B2 | EP2 antagonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2026-05-19 | — | — | US | disclosed |
| EP-4727924-A1 | INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | ONO Pharmaceutical Co., Ltd. (JP) | 2026-04-22 | — | — | EP | disclosed |
| US-12600730-B2 | Substituted cyclopenta[c]pyrroles as ABHD6 antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2026-04-14 | — | — | US | disclosed |
| EP-0422900-B1 | Organic nonlinear optical material and nonlinear optical element | TOSHIBA KK (JP) | 1994-03-16 | — | — | EP | disclosed |
| US-5279921-A | Pattern formation resist and pattern formation method | KABUSHIKI KAISHA TOSHIBA (JP) | 1994-01-18 | — | — | US | disclosed |
| EP-0567090-A2 | Benzoxazepine derivatives as cholinesterase inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-10-27 | — | — | EP | disclosed |
| EP-0422900-A2 | Organic nonlinear optical material and nonlinear optical element | KABUSHIKI KAISHA TOSHIBA (JP) | 1991-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630510-B2 | EP2 antagonist | PTGER2, PTGER1, PTGER4 | RYR2 336/4885TSHR 346/4885CES1 548/4885 |
| US-20040224875-A1 | Inhibitors of glutaminyl cyclase | GLS2, GLS, GLUL | RYR2 3286/4885TSHR 1612/4885CES1 622/4885 |
| US-20100159032-A1 | COMBINATIONS USEFUL FOR THE TREATMENT OF NEURONAL DISORDERS | MME, DNPEP, DPP4 | RYR2 1523/4885TSHR 2536/4885CES1 1069/4885 |
| US-12600730-B2 | Substituted cyclopenta[c]pyrroles as ABHD6 antagonists | ABHD6, ABHD16A, HDHD5 | RYR2 3388/4885TSHR 2561/4885CES1 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.